GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (NAS:SLRX) » Definitions » Interest Coverage

SLRX (Salarius Pharmaceuticals) Interest Coverage : No Debt (1) (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Salarius Pharmaceuticals's Operating Income for the three months ended in Mar. 2025 was $-1.72 Mil. Salarius Pharmaceuticals's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. Salarius Pharmaceuticals has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Salarius Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Salarius Pharmaceuticals's Interest Coverage or its related term are showing as below:

SLRX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


SLRX's Interest Coverage is ranked better than
98.67% of 375 companies
in the Biotechnology industry
Industry Median: 117.6 vs SLRX: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Salarius Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Salarius Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Salarius Pharmaceuticals Interest Coverage Chart

Salarius Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - No Debt No Debt No Debt No Debt

Salarius Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Competitive Comparison of Salarius Pharmaceuticals's Interest Coverage

For the Biotechnology subindustry, Salarius Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Salarius Pharmaceuticals's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Salarius Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Salarius Pharmaceuticals's Interest Coverage falls into.


;
;

Salarius Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Salarius Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Salarius Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-5.73 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Salarius Pharmaceuticals had no debt (1).

Salarius Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, Salarius Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-1.72 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Salarius Pharmaceuticals had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Salarius Pharmaceuticals  (NAS:SLRX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Salarius Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Salarius Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Executives
Tess Burleson director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan I Lieber director C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
William K. Mcvicar director C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421
Arnold C Hanish director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Mark J Rosenblum officer: Exec VP Finance, Interim CFO 3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244
David J. Arthur director, officer: Chief Executive Officer 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Scott Jordan officer: Chief Financial Officer 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Mccreedy Bruce J Jr. director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan P Northrup director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Pao-yu Chuang officer: Controller 2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021
Paul Lammers director 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Boston Foundation, Inc. 10 percent owner 75 ARLINGTON STREET, BOSTON MA 02116
Christoph H Westphal 10 percent owner C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142
Longwood Fund Ii, L.p. 10 percent owner 800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199
Roger D Tung director 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421